Commissioning adiabatic oven testing - an inter-laboratory comparison

Adiabatic oven testing for spontaneous combustion assessment has been a primary method used by the Australian and New Zealand coal industries for input to the development of Principal Hazard Management Plans for mining operations. Consistency of results is important to ensure that the ratings obtained are accurate and reliable for maintaining the integrity of the database used to compare between mines and for obtaining site specific relationships. This paper presents the results from commissioning tests of four new adiabatic ovens at two different laboratories, which show the high level of reproducibility and repeatability needed for confidence in planning of future mining operations. The results cover a range of coal self-heating rates to show the validity of the testing and the reliability of the adiabatic ovens

APP metabolism regulates tau proteostasis in human cerebral cortex neurons.

Accumulation of Aβ peptide fragments of the APP protein and neurofibrillary tangles of the microtubule-associated protein tau are the cellular hallmarks of Alzheimer's disease (AD). To investigate the relationship between APP metabolism and tau protein levels and phosphorylation, we studied human-stem-cell-derived forebrain neurons with genetic forms of AD, all of which increase the release of pathogenic Aβ peptides. We identified marked increases in intracellular tau in genetic forms of AD that either mutated APP or increased its dosage, suggesting that APP metabolism is coupled to changes in tau proteostasis. Manipulating APP metabolism by β-secretase and γ-secretase inhibition, as well as γ-secretase modulation, results in specific increases and decreases in tau protein levels. These data demonstrate that APP metabolism regulates tau proteostasis and suggest that the relationship between APP processing and tau is not mediated solely through extracellular Aβ signaling to neurons.This research was supported by grants from Alzheimer’s Research UK and the Wellcome Trust (to F.J.L.) and core funding to the Gurdon Trust from the Wellcome Trust and Cancer Research UK. N.S. was supported by a Woolf-Fisher Trust (NZ) PhD studentship. H.Z. was supported by the Wolfson Centre at UCL, and the UCLH Dementia BRU provided financial support for the collection of patient materials. F.J.L. is a Wellcome Trust Senior Investigator, K.B. is a Torsten So¨ derberg Academy Professor, and H.Z. is a Wallenberg Academy Fellow.This is the final version. It was first published by Elsevier at http://www.sciencedirect.com/science/article/pii/S2211124715003599

International Consensus Conference on Atopic Dermatitis II (ICCAD II * ): clinical update and current treatment strategies

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/74915/1/j.1365-2133.148.s63.1.x.pd